论文部分内容阅读
为观察溴化异丙托品对慢性阻塞性肺病(COPD)急性加重期患者的支气管扩张作用.60例COPD患者随机分为两组,分别给予溴化异丙托品雾化吸入及氨茶碱口服对照,观察治疗前后对呼吸困难、肺功能FEV1及FVC的影响.结果:溴化异丙托品雾化吸入治疗6d后FEV1及FVC较氨茶碱组增高明显(P<005),溴化异丙托品缓解呼吸困难的有效率明显高于氨茶碱(P<001).结果表明,溴化异丙托品可有效的改善COPD急发期患者的呼吸困难及FEV1,FVC,是一种安全有效的支气管扩张剂
To observe the bronchodilatory effects of ipratropium bromide in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) .60 patients with COPD were randomly divided into two groups, respectively, given ipratropium bromide aerosol inhalation and aminophylline Oral control was used to observe the effect of FEV1 and FVC on dyspnea and pulmonary function before and after treatment.Results: FEV1 and FVC were significantly higher than aminophylline group (P <0.05) after 6 days of inhalation of ipratropium bromide inhalation, The efficacy of ipratropium in alleviating dyspnea was significantly higher than that of aminophylline (P <0.001). The results showed that ipratropium bromide was effective in improving dyspnea and FEV1 and FVC in patients with exacerbation of COPD A safe and effective bronchodilator